Gasdermin: a novel therapeutic target for tumour treatment by activating anti-tumour immunity
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2059-3635
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Gasdermin: a novel therapeutic target for tumour treatment by activating anti-tumour immunity ; volume:5 ; number:1 ; day:13 ; month:5 ; year:2020 ; pages:1-2 ; date:12.2020
Signal transduction and targeted therapy ; 5, Heft 1 (13.5.2020), 1-2, 12.2020
- Creator
-
Fu, Caiyun
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41392-020-0180-4
- URN
-
urn:nbn:de:101:1-2020072019182748343725
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Fu, Caiyun
- SpringerLink (Online service)
Other Objects (12)
Acid affairs in anti-tumour immunity
Let-7i enhances anti-tumour immunity and suppresses ovarian tumour growth
Glutarate regulates T cell metabolism and anti-tumour immunity
Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity
Interleukin-35 promotes progression of prostate cancer and inhibits anti-tumour immunity
The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity
Small tumour microparticle enhances drug delivery efficiency and therapeutic antitumour efficacy
Fractionated Radiotherapy with 3 x 8 Gy Induces Systemic Anti-Tumour Responses and Abscopal Tumour Inhibition without Modulating the Humoral Anti-Tumour Response
RIPK1‐mediated immunogenic cell death promotes anti‐tumour immunity against soft‐tissue sarcoma
Inhibiting glucocorticoid receptor signalling in tumour-associated macrophages for anti-tumour immune response
TT-232: An Anti-tumour and Anti-inflammatory Peptide Therapeutic in Clinical Development
Egr2 and 3 maintain anti-tumour responses of exhausted tumour infiltrating CD8 + T cells
Acid affairs in anti-tumour immunity
Let-7i enhances anti-tumour immunity and suppresses ovarian tumour growth
Glutarate regulates T cell metabolism and anti-tumour immunity
Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity
Interleukin-35 promotes progression of prostate cancer and inhibits anti-tumour immunity
The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity
Small tumour microparticle enhances drug delivery efficiency and therapeutic antitumour efficacy
Fractionated Radiotherapy with 3 x 8 Gy Induces Systemic Anti-Tumour Responses and Abscopal Tumour Inhibition without Modulating the Humoral Anti-Tumour Response
RIPK1‐mediated immunogenic cell death promotes anti‐tumour immunity against soft‐tissue sarcoma
Inhibiting glucocorticoid receptor signalling in tumour-associated macrophages for anti-tumour immune response
TT-232: An Anti-tumour and Anti-inflammatory Peptide Therapeutic in Clinical Development
Egr2 and 3 maintain anti-tumour responses of exhausted tumour infiltrating CD8 + T cells
Acid affairs in anti-tumour immunity
Let-7i enhances anti-tumour immunity and suppresses ovarian tumour growth
Glutarate regulates T cell metabolism and anti-tumour immunity
Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity
Interleukin-35 promotes progression of prostate cancer and inhibits anti-tumour immunity
The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity
Small tumour microparticle enhances drug delivery efficiency and therapeutic antitumour efficacy
Fractionated Radiotherapy with 3 x 8 Gy Induces Systemic Anti-Tumour Responses and Abscopal Tumour Inhibition without Modulating the Humoral Anti-Tumour Response
RIPK1‐mediated immunogenic cell death promotes anti‐tumour immunity against soft‐tissue sarcoma
Inhibiting glucocorticoid receptor signalling in tumour-associated macrophages for anti-tumour immune response
TT-232: An Anti-tumour and Anti-inflammatory Peptide Therapeutic in Clinical Development